Adverse events in the use of HeartMate vented electric and Novacor left ventricular assist devices: Comparing apples and oranges  by Pasque, Michael K. & Rogers, Joseph G.
Adverse events in the use of HeartMate vented electric
and Novacor left ventricular assist devices: Comparing
apples and oranges
Michael K. Pasque, MD
Joseph G. Rogers, MD
There are two Food and Drug Administration–approved, implantable,electrical left ventricular assist devices (LVADs) currently availableto cardiothoracic surgeons for use in patients with end-stage heartfailure. These are the HeartMate vented electric (VE) and Novacordevices, marketed by Thoratec Corporation (Pleasanton, Calif) andWorldHeart Corporation (Ottawa, Ontario, Canada), respectively.
Until recently, objective data concerning device-use end points for these two
LVADs was limited. Device choice, therefore, has been influenced primarily by
single center reports, anecdotal communications, or marketing rhetoric. For the first
time, however, we now have important objective information characterizing antic-
ipated adverse event rates based on clinical outcomes in large multicenter trials and
objective reports of in vitro durability testing. Clinicians who accept the responsi-
bility of using this complex therapy in patients with end-stage heart failure must be
expected to objectively analyze this available information.
First things first. We are the surgical and medical directors of the heart failure
service at Washington University Medical School at Barnes-Jewish Hospital in St
Louis, Missouri. In this capacity, we have served as the institutional principal
investigators of the Novacor bridge-to-transplant and INTrEPID trials at Barnes-
Jewish Hospital. We have no financial interest in, and do not serve on the medical
advisory boards of, either of the companies that market these two devices. We
currently have both devices available at our institution for the treatment of end-stage
heart failure.
Thromboembolism
Both of the currently available LVADs require that nonphysiologic surfaces be
placed in contact with the recipient blood pool, therefore rendering a finite incidence
of thromboembolism as a recognized complication of their use. Much has been
made of the novel textured “biologic” blood-contacting surface of the HeartMate
VE device, which has allowed use of this device without routine systemic antico-
agulation, other than platelet-inhibiting drugs. Much has also been made of the
history of thromboembolism from the smooth “nonbiological” surface of the No-
vacor LVAD and its propensity to thromboembolism despite mandated anticoagu-
lation with heparin or warfarin.
Information concerning thromboembolism is available for these devices from
their respective “user’s manuals” which, in both cases, contain summaries of their
Food and Drug Administration pre-market approval submission data derived from
large multicenter bridge-to-transplant trials.1,2 Obviously, the definitions used in
reporting adverse events are of critical importance in any attempt at comparison.
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These events and their accompanying definitions have been
gathered from user’s manuals, investigator brochures, and
journal publications and are summarized in Table 1. Unfor-
tunately, because of the widely variable, often ill-defined,
and usually overlapping character of the definitions used in
these reports, direct comparison is nearly impossible. For
example, the “neurological dysfunction” rate reported in the
current HeartMate VE user’s manual is 27%,1 whereas an
“embolism (central nervous system)” rate of the Novacor
device is reported in their user’s manual as 26.9%.2 Are
these two rates comparable? Probably not (see Table 1).
Further, two other pertinent event categories are reported in
the Novacor user’s manual. A “neurologic deficit” rate is
reported as 41%,2 whereas a separate non-neurological
thromboembolic event rate of 14.7% is also reported from
the same patient data.2 Unfortunately, a total thromboem-
bolic rate cannot be derived by simply adding these rates
since some patients had events that fit into all three catego-
ries and therefore would be counted three times. The Heart-
Mate VE user’s manual does not report a separate non-
neurological thromboembolic rate although it does report a
global thromboembolic rate of 12%.1
Confused? No doubt. It is obviously difficult, at best, to
compare these rates because of their overlapping and dif-
fering definitions. The HeartMate VE device appears to
have an advantage in the area of thromboembolism and
associated neurological dysfunction. Nonetheless, it is hard
to believe that there was that big of a difference in signif-
icant thromboembolic events, neurological or non-neuro-
logical, between the two devices since 78% of the Novacor
recipients remained transplant candidates and, in fact, sur-
vived to transplantation, compared with 70% of the Heart-
Mate VE recipients.1,2
One possible solution to the lack of uniformity in throm-
boembolic event definitions is for individual centers to
analyze their event rate data by using the definitions used in
reporting the other device’s event rates. For example, the
thromboembolic event rate of our single-center experience
with the Novacor device can be examined with the use of
the HeartMate VE user’s manual definitions of thromboem-
bolic events. In 30 Novacor implants we have seen a “neu-
rological dysfunction” (using the HeartMate VE user’s
manual definition) rate of 20% (compared with 27% re-
ported by the HeartMate VE multicenter study) and a
“thromboembolism” rate of 10% (compared with 12% re-
ported by the HeartMate VE multicenter study). Once again,
our data represent a single-center experience, not a multi-
center trial. In addition, the majority of our Novacor im-
plants were performed after the introduction of the new
conduits (2/98) that reportedly have significantly reduced
the thromboembolic event rate after implantation of the
Novacor device.4
The recently reported REMATCH trial5 (Randomized
Evaluation of Mechanical Assistance for the Treatment of
Congestive Heart Failure) provided additional insights re-
garding the thromboembolic risk of the HeartMate VE
device. Once again, definitions remain problematic. In this
trial, 24% of implant patients had “serious neurological
events,” including “stroke, transient ischemic attacks, and
toxic or metabolic encephalopathy.” Fully 10% of patients
in the device implant group had events that fit study criteria
for an “ischemic stroke.” “Serious” adverse events were
TABLE 1. Neurodysfunction/thromboembolic definitions and rates
Device Adverse event Definition
Rate (%
patients)
HeartMate VE “Neurological dysfunction” “Neurologic dysfunction was defined as any central nervous
system or gross neuromuscular disorder identified by
standard neurologic examination of reflexes, speech, vision,
and so on.”3 “Neurological dysfunction may result from air
emboli, stroke, cerebrovascular accident, temporary
ischemic attack, or hypoperfusion.”1
27%
HeartMate VE “Thromboembolic event” “A thromboembolic event was defined by clinical symptoms
of stroke or by sudden neurologic, pulmonary, renal,
hepatic, or peripheral vascular changes.”3
12%
Novacor “Embolism (CNS)” Any CNS deficit that is sudden in onset and confirmed as
embolic by diagnostic assessment and/or demonstrated to
be infarct related at autopsy.
26.9%
Novacor “Neurologic deficit” Nonembolic CNS deficit diagnosed through comprehensive
neurologic and mental status examinations.
41%
Novacor “Embolism (non-CNS)” Deficit in any non-CNS organ system (pulmonary, renal,
hepatic, splenic, or limb) demonstrated to be due to acute
vascular occlusion.
14.7%
CNS, Central nervous system.
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defined as those adverse events that “caused death or per-
manent disability, were life-threatening, or required or pro-
longed hospitalization.” This trial was performed in an older
group of nontransplant candidates whose risk of “serious
neurological events” would be expected to be higher than in
the bridge-to-transplant patient population.
Anticoagulation
Anticoagulation with heparin, followed by warfarin and
antiplatelet medications, is routinely recommended after
Novacor assist device implantation. According to the user’s
manual accompanying the HeartMate VE device, antiplate-
let medications are recommended, but systemic anticoagu-
lation with heparin or warfarin is not routinely required.
This recommendation deserves further scrutiny in light of
the thromboembolic potential suggested by the above-
described reports, especially when related to other cardio-
vascular conditions for which more aggressive anticoagula-
tion is considered the standard of care. For instance, the
incidence of stroke in a population of patients with chronic
atrial fibrillation is only 5% per year and the incidence of
stroke or valve thrombosis in patients with a St Jude Med-
ical bileaflet mechanical valve (St Jude Medical, Inc, St
Paul, Minn) in the aortic position who are not anticoagu-
lated with warfarin is only 2% to 6% per year.6-13 Yet the
unequivocal recommendation, and certainly the standard of
care in these familiar clinical settings, is routine anticoag-
ulation with heparin or warfarin. The HeartMate VE device
has a frank thromboembolic rate of at least 12% over an
average implant duration of only 112 days. The “neurolog-
ical dysfunction” rate (including transient ischemic attacks)
of 27% suggests that the thromboembolic potential may be
considerably higher. Anticoagulation, however, is still not
routinely recommended.
The recommendation to not anticoagulate may have been
reasonable at the time of this novel device’s introduction.
Unfortunately, the claims do not appear to be borne out by
the subsequent trial data. It is undoubtedly true that some of
the embolic events reported with HeartMate VE LVAD use
were due to device infection, as they are with all LVADs.
These embolic events may or may not have been prevented
by anticoagulation. Nonetheless, it is hard to believe that the
risk of anticoagulation, which is routinely recommended
and used in association with almost all other ventricular
assist devices, outweighs an embolic risk that ranges from
12% to 27%. Just because the HeartMate VE device may (or
may not) have a lower incidence of thromboembolic events
than competing devices does not stand as a rationale for avoid-
ance of anticoagulation in a patient population with such a high
risk of thromboembolism. In light of the available data, avoid-
ance of systemic anticoagulation as the “standard of care” in
these patients warrants reconsideration.
Device Reliability
Information on medical device durability is critical in the
clinical decision-making process regarding the implantation
of all medical devices, let alone those that perform the vital
role of circulatory support. We have come to expect near
perfection in implantable medical devices because of the
reliability records established by many of the medical de-
vice companies. Certainly, the incredible record of the pace-
maker and implantable defibrillator industry, representing a
technology of nearly the same age as the implantable
LVAD, represents the benchmark. With over 30 years of
development, LVAD failure rates, when used in the rela-
tively short average time frame of the bridge-to-transplant
application, could reasonably be expected to be 1% or less.
With the impending reality of the use of these devices as
permanent therapy (in patients with end-stage heart failure
who are not transplant candidates), reliability issues are of
critical importance. Obviously, when clinicians are faced
with decisions regarding possible permanent device implan-
tation in nontransplant candidates, they must have some
reasonable expectation of the potential length of support
that is being offered to their patients by each available
device. In this regard, two sources of reliability information
are available for both devices: in vitro durability testing data
and actual in vivo human use durability information.
In vitro durability testing has been performed in a rela-
tively similar fashion for both devices by their respective
manufacturers. A set number of each of these two devices
were run in vitro to either failure or a fixed termination
period. The data from these studies were then subjected to
reliability modeling to 90% confidence intervals by their
respective manufacturers. The results are documented in
Table 2. The 2-month and 1-year reliability data for the
HeartMate VE device was taken from the HeartMate
SNAP-VE user’s manual.1 To our knowledge, the 2- and
3-year reliability data for the HeartMate VE device have not
been published. The Novacor durability information at
2-month, 1-year, 2-year, and 3-year time periods was taken
from their published test information.2,14
The in vitro durability test information is readily sum-
marized. The predicted Novacor reliability at 2 years ex-
ceeds the HeartMate VE reliability at 2 months. The Nova-
cor device is as reliable at 3 years as the HeartMate VE
device is at 1 year.
Clinical use reliability information is also available from
several published sources. Although the device failure rate
was reported as only 1% in the HeartMate VE bridge-to-
TABLE 2. In vitro reliability testing
Device 2 mo 1 y 2 y 3 y
HeartMate VE 93.5% 84.7%
Novacor 99.9% 99.9% 98.3% 85.9%
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transplant trial, 9% of patients had to hand pump or hook
their device to the pneumatic console because of component
failure.1,3 In other words, nearly 1 of every 10 patients had
serious device component failure at an average implant
duration of 112 days (4 months). Admirably, 72% of the
patients who used the unique back-up components of the
HeartMate VE device survived to transplantation. Failure
modes were apparently multiple and usually not predictable.
In addition, the REMATCH trial supplies more clinical
use information on the durability of the HeartMate VE
device over a longer implant duration. Of considerable impor-
tance, there were no system failures that caused death or
resulted in device replacement at 12 months of follow-up.5
Probability of device failure, however, at 24 months was 35%.
The device was replaced in 10 patients. Failure of the LVAD
resulted in 7 deaths in a cohort of only 22 patients who were
“at risk” beyond 12 months of support duration. Once again,
multiple failure modes were demonstrated, including inflow
valve failure, outflow graft erosion, rupture of the lining, motor
failure, and wear on the bearings.5
Information regarding the reliability of the Novacor
device during clinical use is available from the US and
European bridge-to-transplant experience. Unfortunately,
well-documented clinical longevity information, as of-
fered by the HeartMate VE REMATCH Trial, is not
available because of the early status of the Novacor
INTrEPID trial. In the US and European bridge use,
however, it is noteworthy that 7 Novacor patients were
supported beyond 3 years with 2 of these patients sup-
ported beyond 4 years. In more than 1300 implants,
representing 361 patient-years of support, there has been
only one documented case of pump failure resulting in device
stoppage (from an encapsulation leak that fouled the electron-
ics on the first postoperative day) that required immediate
device replacement. To date, wear of the pump main bearing
represents the only long-term device failure mode. Bearing
wear is apparently detectable by device parameter interroga-
tion and tracking and has allowed elective device replacement
on 6 occasions during long-term support.
Conclusion
When compared with other available devices, the Heart-
Mate VE LVAD appears to have an admirable record with
regard to thromboembolic event rates, even without sys-
temic anticoagulation in the majority of the reported pa-
tients. Whether routine anticoagulation in all patients would
have resulted in a further reduction of thromboembolic rates
is unknown. The Novacor thromboembolic rates appear to
be higher than those reported with the HeartMate VE de-
vice, although the often unknown, overlapping, and widely
disparate definitions of thromboembolic events make direct
comparison difficult. Despite the apparent advantage in
thromboembolic event rates demonstrated by the HeartMate
VE bridge-to-transplant trial, the actual rate of clinically
significant thromboembolic events may not have differed
widely from the Novacor bridge experience. This is sug-
gested by the fact that an apparently higher percentage of
the Novacor bridge patients remained transplant candidates
and actually survived to transplantation (78%) than in the
HeartMate VE bridge trial (70%).
The HeartMate VE continues to have an advantage
over the Novacor device in that anticoagulation with
heparin and warfarin is not routinely recommended. The
threat of stroke, transient ischemic attack, and non-
neurological peripheral embolism is not, however, elim-
inated by the “biologic” surface of the HeartMate VE
device. Quite to the contrary, the neurological dysfunc-
tion and thromboembolic rates documented in the bridge-
to-transplant and REMATCH trials are considerable, es-
pecially considering that a significant number of these
patients received warfarin at some point during their
support. The combined thromboembolic rate of the
HeartMate VE device, which may be several fold higher
than that reported in unanticoagulated patients who have
chronic atrial fibrillation or who have a St Jude Medical me-
chanical valve in the aortic position, would indicate that the
routine recommendation for isolated antiplatelet therapy, with-
out heparin or warfarin, may deserve reexamination.
The mechanical failure rate of the HeartMate VE device
is of considerable concern. To our knowledge, this failure
rate far exceeds that associated with any implantable me-
chanical device that is currently used to treat any other
medical condition in the United States. The fact that the
failure modes are multiple and unpredictable suggest that
attempts to retro-fix the problems may be problematic. This
is of specific concern when the clinical goal is permanent
implantation for long-term circulatory support in patients
with end-stage heart failure.
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